Your browser is no longer supported. Please, upgrade your browser.
EQ Equillium, Inc. monthly Stock Chart
Equillium, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own4.50% Shs Outstand21.37M Perf Week-0.41%
Market Cap120.88M Forward P/E- EPS next Y-1.43 Insider Trans-19.85% Shs Float13.79M Perf Month-2.78%
Income-28.50M PEG- EPS next Q-0.39 Inst Own34.30% Short Float4.97% Perf Quarter-3.16%
Sales- P/S- EPS this Y-35.50% Inst Trans106.50% Short Ratio0.48 Perf Half Y63.33%
Book/sh3.66 P/B1.34 EPS next Y7.10% ROA-47.00% Target Price- Perf Year19.12%
Cash/sh3.67 P/C1.34 EPS next 5Y- ROE-60.80% 52W Range2.20 - 27.05 Perf YTD44.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.89% Beta-
Dividend %- Quick Ratio17.90 Sales past 5Y- Gross Margin- 52W Low122.73% ATR0.58
Employees26 Current Ratio17.90 Sales Q/Q- Oper. Margin- RSI (14)46.91 Volatility8.25% 14.04%
OptionableNo Debt/Eq0.13 EPS Q/Q10.80% Profit Margin- Rel Volume0.30 Prev Close4.93
ShortableYes LT Debt/Eq0.12 Earnings- Payout- Avg Volume1.42M Price4.90
Recom1.20 SMA204.62% SMA50-9.15% SMA200-6.36% Volume430,264 Change-0.61%
Jul-14-20Reiterated H.C. Wainwright Buy $14 → $24
Jul-10-20Resumed Stifel Buy $22 → $10
Feb-22-19Initiated SVB Leerink Outperform $16
Nov-30-20 09:30PM  
Nov-26-20 10:24AM  
Nov-25-20 08:46AM  
Nov-10-20 04:05PM  
Nov-06-20 08:35AM  
Nov-04-20 08:35AM  
Oct-29-20 04:13PM  
Oct-13-20 11:30AM  
Sep-17-20 04:07PM  
Sep-15-20 08:07AM  
Sep-03-20 04:07PM  
Aug-18-20 04:05PM  
Aug-13-20 09:42PM  
Aug-12-20 08:37AM  
Aug-11-20 08:20AM  
Aug-10-20 04:07PM  
Jul-30-20 04:07PM  
Jul-14-20 11:47AM  
Jul-13-20 07:33AM  
Jun-03-20 09:00AM  
May-21-20 04:07PM  
May-13-20 04:07PM  
May-07-20 04:07PM  
Mar-30-20 04:07PM  
Mar-26-20 04:07PM  
Feb-27-20 04:14PM  
Feb-13-20 04:07PM  
Jan-29-20 04:07PM  
Jan-28-20 07:33AM  
Jan-09-20 10:01AM  
Jan-03-20 09:52AM  
Dec-22-19 06:41PM  
Dec-12-19 07:00AM  
Dec-10-19 07:56AM  
Dec-09-19 04:10PM  
Nov-26-19 04:07PM  
Nov-15-19 08:05AM  
Nov-12-19 04:07PM  
Nov-07-19 04:07PM  
Nov-06-19 08:05AM  
Oct-31-19 09:14AM  
Oct-01-19 04:05PM  
Sep-19-19 11:51AM  
Sep-17-19 04:07PM  
Aug-27-19 04:07PM  
Aug-12-19 04:07PM  
Jul-10-19 08:07AM  
May-23-19 04:07PM  
May-13-19 04:07PM  
May-06-19 08:30AM  
Apr-16-19 04:07PM  
Mar-28-19 04:07PM  
Mar-27-19 04:07PM  
Feb-26-19 04:07PM  
Feb-21-19 04:07PM  
Feb-19-19 04:07PM  
Feb-07-19 08:08AM  
Dec-19-18 08:06AM  
Nov-15-18 04:07PM  
Nov-01-18 04:07PM  
Oct-12-18 08:25AM  
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Connelly StephenChief Scientific OfficerSep 28Sale5.6225,000140,3951,018,000Sep 30 05:00 PM
Connelly StephenChief Scientific OfficerJul 13Sale8.13250,0002,033,4751,043,000Jul 15 05:00 PM
Keyes Jason AChief Financial OfficerFeb 18Sale5.035,00025,138130,520Feb 19 05:48 PM
Keyes Jason AChief Financial OfficerJan 21Sale4.415,00022,043135,520Jan 22 08:13 PM